These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29436464)

  • 1. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit.
    Gillis HC; Fischer G; Gupta S
    Am J Health Syst Pharm; 2018 Feb; 75(4):171-172. PubMed ID: 29436464
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension.
    Petros AJ; Turner SC; Nunn AJ
    J Pharm Technol; 1995; 11(4):163-6. PubMed ID: 10144080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled epoprostenol.
    Lusardi P; Brown V
    Am J Nurs; 2003 Jul; 103(7):64AA, 64CC, 64EE, 64GG-64HH. PubMed ID: 12865644
    [No Abstract]   [Full Text] [Related]  

  • 5. Unsuccessful treatment of pulmonary hypertension by inhaled nitric oxide and aerosolized prostacyclin.
    Barry PW
    Anaesth Intensive Care; 1999 Dec; 27(6):670-1. PubMed ID: 10631434
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy for primary pulmonary hypertension.
    McCormack D
    Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with ARDS.
    Dahlem P
    Intensive Care Med; 1999 Dec; 25(12):1474-5. PubMed ID: 10660861
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Complications with the Delivery of Inhaled Epoprostenol in the Operating Room.
    Bhatt AM; Stein EJ
    Anesthesiology; 2017 Aug; 127(2):383. PubMed ID: 28323647
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostacyclin in the intensive care setting.
    Ivy DD
    Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S41-5. PubMed ID: 20216163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled Nitric Oxide (iNO) and Inhaled Epoprostenol (iPGI
    Rao V; Ghadimi K; Keeyapaj W; Parsons CA; Cheung AT
    J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1452-1457. PubMed ID: 29336971
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.
    Torbic H; Szumita PM; Anger KE; Nuccio P; LaGambina S; Weinhouse G
    J Crit Care; 2013 Oct; 28(5):844-8. PubMed ID: 23683572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
    El-Kersh K; Smith JS
    Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
    [No Abstract]   [Full Text] [Related]  

  • 13. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives.
    Bratel T; Lagerstrand L; Brodin LA; Nowak J; Randmaa I
    Chest; 2005 Dec; 128(6 Suppl):615S-616S. PubMed ID: 16373868
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
    Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis.
    Parameswaran K; Purcell I; Farrer M; Holland C; Taylor IK; Keaney NP
    Respir Med; 1999 Feb; 93(2):75-8. PubMed ID: 10464856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
    Bildirici I; Shumway JB
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery.
    McGinn K; Reichert M
    Ann Pharmacother; 2016 Jan; 50(1):22-6. PubMed ID: 26438636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled Pulmonary Vasodilators: Are There Indications Within the Pediatric ICU?
    Kuch BA; Saville AL; Sanchez De Toledo J; Venkataraman ST
    Respir Care; 2017 Jun; 62(6):678-698. PubMed ID: 28546372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol.
    Ramsay MA; Spikes C; East CA; Lynch K; Hein HA; Ramsay KJ; Klintmalm GB
    Anesthesiology; 1999 Jan; 90(1):299-301. PubMed ID: 9915339
    [No Abstract]   [Full Text] [Related]  

  • 20. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.